Shares of Fresenius Medical Care AG (NYSE:FMS) saw unusually-strong trading volume on Wednesday . Approximately 175,713 shares were traded during trading, a decline of 7% from the previous session’s volume of 188,089 shares.The stock last traded at $44.60 and had previously closed at $43.76.

Several equities research analysts recently issued reports on FMS shares. Jefferies Group raised Fresenius Medical Care AG from an “underperform” rating to a “hold” rating in a research note on Friday, July 8th. Royal Bank Of Canada restated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Tuesday, May 24th. Robert W. Baird restated a “hold” rating on shares of Fresenius Medical Care AG in a research report on Monday, May 16th. Zacks Investment Research upgraded Fresenius Medical Care AG from a “sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Sanford C. Bernstein began coverage on Fresenius Medical Care AG in a research report on Monday, April 11th. They set an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the stock. Fresenius Medical Care AG currently has a consensus rating of “Hold” and an average price target of $42.50.

The company has a 50-day moving average of $42.84 and a 200-day moving average of $42.82. The company has a market cap of $27.11 billion and a PE ratio of 25.83.

Fresenius Medical Care AG (NYSE:FMS) last posted its quarterly earnings data on Tuesday, May 3rd. The company reported $0.75 EPS for the quarter, topping the consensus estimate of $0.42 by $0.33. The company earned $4.21 billion during the quarter, compared to analysts’ expectations of $4.25 billion. The company’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.69 earnings per share. Analysts expect that Fresenius Medical Care AG will post $2.03 EPS for the current year.

A number of hedge funds and institutional investors have recently modified their holdings of the company. Neuberger Berman Group LLC increased its position in shares of Fresenius Medical Care AG by 8.2% in the fourth quarter. Neuberger Berman Group LLC now owns 35,128 shares of the company’s stock valued at $1,470,000 after buying an additional 2,649 shares in the last quarter. Comerica Bank increased its position in shares of Fresenius Medical Care AG by 5.4% in the fourth quarter. Comerica Bank now owns 35,387 shares of the company’s stock valued at $1,486,000 after buying an additional 1,798 shares in the last quarter. WBI Investments Inc. purchased a new position in shares of Fresenius Medical Care AG during the fourth quarter valued at $2,249,000. Bank of Montreal Can increased its position in shares of Fresenius Medical Care AG by 60.0% in the fourth quarter. Bank of Montreal Can now owns 56,700 shares of the company’s stock valued at $2,373,000 after buying an additional 21,264 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Fresenius Medical Care AG by 3.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 107,376 shares of the company’s stock valued at $4,493,000 after buying an additional 3,694 shares in the last quarter.

Fresenius Medical Care AG & Co KGaA (FMC AG & CO. KGAA) is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end stage renal disease (ESRD), as well as other healthcare services. The Company operates through four segments: North America, Europe, Middle East, Africa (EMEA), Asia-Pacific and Latin America.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.